In the premarket trading session, at last check, Virios Therapeutics Inc. (VIRI) shares had plunged by -11.65% to trade at $5.99. VIRI stock previously closed the session on Monday to a gain of 12.25% at $6.78. The VIRI stock volume traded 2.49 million shares. VIRI shares have moved up in the past week by 14.72%. In the past three and six months, the VIRI stock has gained 25.09% and shed -59.43% respectively. Furthermore, Virios Therapeutics Inc. is currently valued in the market at $56.82 million and has 8.33 million outstanding shares.
What you need to know about Virios Therapeutics Inc.
Virios Therapeutics Inc. is a development stage biotech company that specifically focuses on the design and development of unmet needs of the health and patient market. The company has a platform for developing antiviral therapies that particularly treat viral triggered abnormal immune response and diseases associated with it. Virios is also developing therapies to treat fibromyalgia through a fixed dose of famciclovir and celecoxib combination. The lead development candidate for fibromyalgia treatment is known as IMC-1. The company was initially known as Virios Therapeutics LLC until December 2020 and has its origin based in 2012 with the headquarter in Alpharetta, Georgia.
Significance of the positive phase2a results in clinical trials of PRID-201
The company has announced positive results in the Phase 2a clinical trials of PRID-201. The results primarily suggested that the IMC-1 which is being developed by VIRI stock for the treatment of fibromyalgia, has shown better tolerance than placebo in the fibromyalgia patients. IMC-1 is created through the combination of famciclovir and celecoxib and suppresses Herpes Simplex Virus-1 synergistically.
In the World Congress of International Association for the Study of Pain (IASP) which was held on 9-11 and 16-18 June 2021, Viriospresented a poster presentation of the results and potential of IMC-1. There is a reasonable clinical requirement for new, protected and powerful medicines with the possibility to improve care for the assessed 10 – 20 million FM patients in the U.S. what’s more, in excess of 200 million around the world. Phase 2a clinical preliminary information showed that IMC-1 treated patients had higher in general finishing rates and lower paces of stopping because of unfriendly occasions, as contrasted and fake treatment treated patients. This is a particularly promising outcome when seen behind the scenes of current patient and supplier disappointment with the by and large helpless bearableness of existing endorsed FM medicines.
IMC‑1 showed an empowering wellbeing profile, as AEs happened at a lower rate and were less serious in the IMC‑1 treatment bunch contrasted and fake treatment. The suspension rate because of AEs was almost 3‑fold higher in patients getting placebo treatment contrasted and patients getting IMC‑1, proposing that treatment with IMC‑1 was surprisingly well‑tolerated. In this examination, IMC‑1 exhibited critical decreases in torment, exhaustion, and other significant indications in patients with FM. These outcomes recommend that IMC‑1 may offer a promising and well‑tolerated choice to treat patients with FM.
